dupilumab · Dupixent

Monoclonal antibody

Also known as REGN668

Approvedregulatory verdict

Evidence outlook

Approved: Asthma, Atopic Dermatitis, Chronic Obstructive Pulmonary Disease, Chronic Spontaneous Urticaria, Prurigo Nodularis, Eosinophilic Esophagitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (7)
US
  • Allergic Fungal Rhinosinusitis: DUPIXENT for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgeryOutside this platform's coverageajmc.com
  • Treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgeryOutside this platform's coverageFDA label
  • Chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoidFDA label
Product first approved 2017
CN
  • Dupixent as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils
Product first approved 2024sanofi.com
JP
  • Treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments
Product first approved 2018PMDA
CA
  • Atopic Dermatitis DUPIXENT (dupilumab injection) is indicated for the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. Asthma DUPIXENT is indicated as an add-on maintenance treatment in patients aged 6 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma. DUPIXENT is not indicated for relief of acute bronchospasm...
Product first approved 2017Health Canada
EU
  • Atopic dermatitis Adults and adolescents Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Children 6 months to 11 years of age Dupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. Asthma Adults and adolescents Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood...
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (46)
Asthma
NCT07309614 · Université de Sherbrooke
2026-01-29 – 2030-01 · Asthma Control
What this study did
NCT06191315 · Sanofi
2024-01-03 – 2028-12-21 · Wheezing, Asthma
What this study did
NCT06461949 · National Institute on Deafness and Other Communication Disorders (NIDCD)
2024-07-17 – 2024-07-17 · Allergic Fungal Rhinosinusitis (AFRS), Chronic Rhinosinusitis (CRS), Asthma, Nasal Polyps
What this study did
NCT03884842 · McMaster University
2019-07-01 – 2023-01-17 · Asthma
What this study did
NCT03620747 · Sanofi
2018-08-30 – 2022-02-18 · Asthma
What this study did
Atopic Dermatitis
NCT07919899 · Sanofi
2026-11-30 – 2028-07-25 · Dermatitis Atopic
What this study did
NCT06389136 · AbbVie
2024-06-14 – 2027-05 · Atopic Dermatitis
What this study did
NCT02612454 · Regeneron Pharmaceuticals
2015-10-15 – 2026-10-09 · Atopic Dermatitis
What this study did
NCT04678882 · Sanofi
2021-01-15 – 2023-10-28 · Atopic Dermatitis
What this study did
NCT03738397 · AbbVie
2019-02-21 – 2020-12-09 · Atopic Dermatitis
What this study did
NCT03912259 · Sanofi
2018-12-19 – 2020-02-14 · Atopic Dermatitis
What this study did
Chronic Obstructive Pulmonary Disease
Chronic Spontaneous Urticaria
Eosinophilic Esophagitis
NCT07112378 · Regeneron Pharmaceuticals
2025-11-10 – 2028-10-09 · Eosinophilic Esophagitis (EoE)
What this study did
Prurigo Nodularis
NCT06293053 · Sanofi
2024-05-15 – 2027-11-03 · Prurigo Nodularis
What this study did
Other / comorbidity
NCT04684524 · Sanofi
2020-12-01 – 2025-03-07 · Allergic Fungal Rhinosinusitis
What this study did
NCT05878093 · Sanofi
2023-05-16 – 2024-11-28 · Chronic Rhinosinusitis With Nasal Polyps
What this study did
NCT05545072 · Emory University
2023-10-26 – 2024-07-10 · Allergic Fungal Rhinosinusitis
What this study did
NCT02898454 · Sanofi
2016-11-28 – 2018-11-16 · Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
What this study did
NCT02912468 · Sanofi
2016-12-05 – 2018-07-05 · Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
What this study did
Phase 2/3 (4)
Atopic Dermatitis
Other / comorbidity
NCT05535738 · Wei-Che Ko
2022-11-15 – 2027-12-31 · Skin Inflammation, Allergic Contact Dermatitis
What this study did
NCT04206553 · Regeneron Pharmaceuticals
2020-10-28 – 2025-01-05 · Bullous Pemphigoid
What this study did
NCT04244006 · University Hospital, Toulouse
2020-07-23 – 2022-11-15 · Netherton Syndrome
What this study did
Phase 2 (51)
Asthma
NCT05720325 · The University of Texas Health Science Center at San Antonio
2023-03-29 – 2027-11-01 · Asthma, Allergic
What this study did
NCT05347771 · National Institute of Allergy and Infectious Diseases (NIAID)
2022-05-04 – 2027-03-15 · Asthma
What this study did
NCT05575037 · Brigham and Women's Hospital
2023-08-01 – 2026-12-30 · Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
What this study did
NCT03387852 · Sanofi
2018-03-12 – 2019-08-07 · Asthma
What this study did
NCT02573233 · Sanofi
2016-01-27 – 2018-01-03 · Asthma
What this study did
NCT01312961 · Sanofi
2011-03 – 2012-10 · Asthma
What this study did
Atopic Dermatitis
NCT03359356 · Icahn School of Medicine at Mount Sinai
2018-01-09 – 2020-12-17 · Alopecia Areata
What this study did
NCT03736967 · Regeneron Pharmaceuticals
2018-11-12 – 2020-07-28 · Atopic Dermatitis
What this study did
NCT02407756 · Regeneron Pharmaceuticals
2015-03-31 – 2016-03-31 · Atopic Dermatitis
What this study did
NCT02210780 · Regeneron Pharmaceuticals
2014-08-05 – 2015-09-15 · Atopic Dermatitis
What this study did
NCT01979016 · Regeneron Pharmaceuticals
2013-12-31 – 2015-01-31 · Atopic Dermatitis (AD)
What this study did
NCT01859988 · Regeneron Pharmaceuticals
2013-05 – 2014-09 · Atopic Dermatitis
What this study did
NCT01548404 · Regeneron Pharmaceuticals
2012-04 – 2013-06 · Atopic Dermatitis
What this study did
Chronic Spontaneous Urticaria
NCT03749135 · Charite University, Berlin, Germany
2018-11-12 – 2021-07-07 · Chronic Spontaneous Urticaria, Recurrent Angioedema
What this study did
Eosinophilic Esophagitis
NCT06705387 · University of Colorado, Denver
2024-12-23 – 2027-03 · Eosinophilic Esophagitis
What this study did
NCT02379052 · Regeneron Pharmaceuticals
2015-05-12 – 2017-07-10 · Eosinophilic Esophagitis
What this study did
Other / comorbidity
NCT05866562 · Icahn School of Medicine at Mount Sinai
2024-07-11 – 2029-04-30 · Alopecia Areata
What this study did
NCT07908563 · Icahn School of Medicine at Mount Sinai
2026-08-27 – 2028-12 · Major Depressive Disorder
What this study did
NCT05551793 · Emma Guttman
2023-04-10 – 2028-10-31 · Alopecia Areata
What this study did
NCT07091175 · National University Hospital, Singapore
2025-11-27 – 2028-02-28 · Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent
What this study did
NCT06226610 · Akron Children's Hospital
2024-11-21 – 2027-12-31 · Pruritis
What this study did
NCT06477653 · National Institute of Allergy and Infectious Diseases (NIAID)
2025-02-05 – 2027-03-30 · Hypereosinophilic Syndrome
What this study did
NCT04600362 · Technical University of Munich
2021-03-30 – 2027-01-31 · Nummular Eczema
What this study did
NCT05831176 · Regeneron Pharmaceuticals
2023-05-03 – 2026-11-25 · Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
What this study did
NCT05031455 · Scripps Clinic
2024-03-25 – 2026-04-20 · Aspirin-exacerbated Respiratory Disease
What this study did
NCT04362501 · Johns Hopkins University
2020-10-15 – 2025-09-30 · Chronic Sinusitis
What this study did
NCT04430179 · University of South Florida
2020-12-17 – 2025-07 · Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
What this study did
NCT05128383 · Beth Israel Deaconess Medical Center
2023-01-13 – 2025-06-10 · Keloid
What this study did
NCT03679676 · Stanford University
2020-02-05 – 2025-05-02 · Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
What this study did
NCT04148352 · Andrew J Long, PharmD
2021-10-18 – 2025-02-25 · Allergies Food Milk
What this study did
NCT04502966 · National Institute of Allergy and Infectious Diseases (NIAID)
2020-11-05 – 2025-02-20 · Allergic Rhinoconjunctivitis, Grass Pollen Allergy
What this study did
NCT04296864 · Andover Eye Associates
2020-02-10 – 2025-01 · Atopic Keratoconjunctivitis
What this study did
NCT03678545 · Children's Hospital Medical Center, Cincinnati
2021-05-15 – 2024-11-13 · Eosinophilic Gastritis, Eosinophilic Gastroenteritis
What this study did
NCT04256759 · Mayo Clinic
2020-09-01 – 2024-09-06 · Pruritus
What this study did
NCT05967884 · Ottawa Hospital Research Institute
2023-08-04 – 2024-08-01 · Breast Cancer
What this study did
NCT04442269 · Regeneron Pharmaceuticals
2020-09-15 – 2024-02-09 · Allergic Bronchopulmonary Aspergillosis
What this study did
NCT04678856 · Sanofi
2020-12-02 – 2024-01-29 · Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder
What this study did
NCT03861455 · University Hospital, Toulouse
2019-07-15 – 2023-12-20 · Chronic Hand Eczema
What this study did
NCT04200755 · University of Cologne
2020-05-19 – 2023-11-30 · Localized Scleroderma
What this study did
NCT04920916 · University of Virginia
2021-05-25 – 2023-04-18 · COVID-19
What this study did
NCT03749148 · Charite University, Berlin, Germany
2018-12-10 – 2023-02-28 · Cholinergic Urticaria
What this study did
NCT04512339 · University Medical Center Groningen
2020-08-01 – 2022-08 · Hand Eczema
What this study did
NCT03682770 · Regeneron Pharmaceuticals
2018-10-03 – 2021-07-23 · Peanut Allergy
What this study did
NCT03793608 · Regeneron Pharmaceuticals
2019-03-12 – 2021-05-12 · Peanut Allergy
What this study did
NCT03886493 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-08-28 – 2020-10-06 · Prostate Cancer
What this study did
NCT03595488 · Rochester General Hospital
2018-09-05 – 2019-12-11 · Aspirin-exacerbated Respiratory Disease
What this study did
NCT03558997 · Regeneron Pharmaceuticals
2018-06-07 – 2019-06-13 · Allergic Rhinitis
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT07277322 · Dan Feng
2026-09-01 – 2030-12-31 · Metastatic Colorectal Cancer, Liver Metastases
What this study did
Dupilumab_Metastatic NSCLCactive not recruiting
NCT05013450 · Thomas Marron
2021-09-10 – 2030-09-18 · Metastatic Non-small Cell Lung Cancer
What this study did
NCT06088771 · Icahn School of Medicine at Mount Sinai
2024-10-09 – 2027-07-01 · Non-Small Cell Lung Cancer
What this study did
Phase 1 (18)
Asthma
NCT03112577 · Regeneron Pharmaceuticals
2017-06-15 – 2019-12-09 · Asthma, Allergic
What this study did
Atopic Dermatitis
NCT05372003 · Mayo Clinic
2022-08-09 – 2024-02-23 · Atopic Dermatitis
What this study did
NCT03050151 · Regeneron Pharmaceuticals
2017-02-28 – 2018-02-12 · Atopic Disorders, Eczema, Atopic
What this study did
NCT02647086 · Regeneron Pharmaceuticals
2015-12 – 2016-07 · Atopic Dermatitis
What this study did
NCT01259323 · Regeneron Pharmaceuticals
2010-12 – 2012-07 · Dermatitis
What this study did
NCT01385657 · Regeneron Pharmaceuticals
2011-07-31 – 2012-03-31 · Atopic Dermatitis
What this study did
Eosinophilic Esophagitis
NCT07358234 · Mayo Clinic
2026-02-04 – 2027-12 · Eosinophilic Esophagitis (EoE)
What this study did
Other / comorbidity
NCT05649098 · Northwestern University
2023-06-12 – 2032-06-01 · Skin Diseases
What this study did
NCT06637306 · Rima Patel
2025-03-05 – 2027-03-10 · Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
What this study did
NCT03675022 · Brigham and Women's Hospital
2018-08-15 – 2022-07-01 · Sleep Apnea, Rhinosinusitis Chronic
What this study did
NCT05976386 · Sanofi
2021-06-08 – 2021-09-24 · Healthy Volunteers
What this study did
NCT05976373 · Sanofi
2015-01-05 – 2015-03-30 · Healthy Volunteers
What this study did
NCT05976360 · Sanofi
2014-11-02 – 2015-01-17 · Healthy Volunteer
What this study did
NCT01537653 · Sanofi
2012-03 – 2012-10 · Healthy
What this study did
NCT01537640 · Sanofi
2012-02 – 2012-07 · Healthy
What this study did
NCT01484600 · Regeneron Pharmaceuticals
2011-12 – 2012-02 · Healthy
What this study did
NCT01015027 · Regeneron Pharmaceuticals
2009-10 – 2010-07 · Healthy
What this study did
Phase 4 (57)
Asthma
NCT06818019 · University Hospital, Toulouse
2025-12-15 – 2029-12-31 · Severe Asthma
What this study did
NCT04743791 · Sally E. Wenzel MD
2022-10-17 – 2028-06 · Asthma
What this study did
NCT06385236 · University of California, San Diego
2024-02-19 – 2028-01-31 · Moderate to Severe Asthma
What this study did
NCT03694158 · Boston Children's Hospital
2021-09-08 – 2027-03 · Asthma
What this study did
NCT04380038 · University of Virginia
2022-05-01 – 2026-12-31 · Asthma
What this study did
NCT05942222 · Copenhagen University Hospital, Rigshospitalet
2023-04-27 – 2026-05-01 · Chronic Rhinosinusitis With Nasal Polyps, Asthma; Eosinophilic, Eosinophilia
What this study did
NCT06556264 · Dr. Andrew Thamboo, MD
2024-08 – 2025-12 · Chronic Rhinosinusitis With Nasal Polyps, Asthma
What this study did
NCT04998604 · Sanofi
2021-09-27 – 2024-12-27 · Chronic Rhinosinusitis With Nasal Polyps, Asthma
What this study did
NCT04203797 · Regeneron Pharmaceuticals
2020-07-16 – 2023-07-15 · Asthma
What this study did
NCT05036733 · University of Michigan
2022-02-22 – 2023-06-29 · Asthma
What this study did
Atopic Dermatitis
NCT07905547 · Sanofi
2026-10-28 – 2028-08-02 · Atopic Dermatitis
What this study did
NCT05858619 · University of California, San Francisco
2023-02-01 – 2028-02-01 · Atopic Dermatitis
What this study did
NCT07187089 · Regeneron Pharmaceuticals
2025-11-11 – 2028-01-05 · Severe Atopic Dermatitis (AD)
What this study did
NCT05268107 · University of Michigan
2023-01-25 – 2028-01 · Atopic Dermatitis
What this study did
NCT05042258 · Northwestern University
2024-08-12 – 2027-06 · Atopic Dermatitis, Sleep Disturbance
What this study did
NCT05983068 · Sanofi
2024-02-22 – 2027-05-19 · Dermatitis Atopic
What this study did
NCT06004986 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2023-08-14 – 2026-12-31 · Atopic Dermatitis, Atopic Dermatitis Eczema
What this study did
NCT05642208 · Nantes University Hospital
2023-03-08 – 2026-08-27 · Atopic Dermatitis, Eczema, Atopic
What this study did
NCT06116526 · Johns Hopkins University
2024-04-01 – 2026-07-18 · Atopic Dermatitis
What this study did
NCT05436535 · National Institute of Allergy and Infectious Diseases (NIAID)
2022-11-21 – 2025-10-24 · Atopic Dermatitis
What this study did
NCT05285839 · Psoriasis Treatment Center of Central New Jersey
2022-04-19 – 2024-12-15 · Atopic Dermatitis
What this study did
NCT05590585 · Regeneron Pharmaceuticals
2023-01-11 – 2024-11-14 · Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
What this study did
NCT05680298 · Sanofi
2023-02-22 – 2024-03-15 · Atopic Dermatitis
What this study did
NCT05265234 · OptiSkin Medical
2022-03-01 – 2024-03-01 · Eczema, Atopic Dermatitis
What this study did
NCT05624112 · Sanofi
2022-11-25 – 2024-01-25 · Atopic Dermatitis, Dermatitis Atopic
What this study did
NCT04895423 · National Medical Research Center for Children's Health, Russian Federation
2021-11-25 – 2023-07-25 · Atopic Dermatitis
What this study did
NCT03293030 · University of California, San Francisco
2018-10-22 – 2023-02-23 · Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Atopic Dermatitis and Related Conditions
What this study did
NCT03667014 · University of California, San Francisco
2018-11-01 – 2022-12-15 · Atopic Dermatitis, Atopic Dermatitis Eczema
What this study did
NCT04718870 · Sanofi
2021-02-19 – 2022-11-30 · Dermatitis Atopic
What this study did
NCT04358224 · Jonathan A. Bernstein, MD
2020-09-01 – 2022-11-18 · Atopic Dermatitis, Eczema
What this study did
NCT04823130 · Sanofi
2021-04-22 – 2022-08-30 · Dermatitis Atopic
What this study did
NCT04033367 · Sanofi
2019-08-22 – 2021-10-06 · Atopic Dermatitis
What this study did
NCT04447417 · Sanofi
2020-07-16 – 2021-06-17 · Atopic Dermatitis
What this study did
NCT04520308 · Eric Simpson
2020-09-01 – 2021-03-31 · Atopic Dermatitis, AD, Eczema
What this study did
NCT03389893 · National Institute of Allergy and Infectious Diseases (NIAID)
2018-07-25 – 2020-09-09 · Atopic Dermatitis (AD)
What this study did
Chronic Obstructive Pulmonary Disease
NCT07053423 · Sanofi
2025-09-22 – 2029-02-02 · Chronic Obstructive Pulmonary Disease
What this study did
Eosinophilic Esophagitis
NCT06352073 · University of North Carolina, Chapel Hill
2024-05-16 – 2026-12 · Eosinophilic Esophagitis, EoE
What this study did
NCT06665971 · University of California, San Diego
2024-11-10 – 2026-11-14 · Eosinophilic Esophagitis (EoE)
What this study did
NCT05247866 · Children's Hospital of Philadelphia
2022-06-16 – 2025-01-21 · Eosinophilic Esophagitis
What this study did
Other / comorbidity
NCT06188871 · University of Rochester
2024-06-01 – 2027-06-01 · Chronic Rhinosinusitis With Nasal Polyps
What this study did
NCT03935971 · Brigham and Women's Hospital
2019-12-18 – 2027-03-31 · Allergic Contact Dermatitis
What this study did
NCT05094570 · University of Virginia
2022-09-01 – 2026-12-31 · Nasal Polyps, Staphylococcus Aureus
What this study did
NCT04869436 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2021-07-19 – 2026-09-16 · Chronic Rhinosinusitis With Nasal Polyps, Olfactory Disorder
What this study did
NCT06750471 · Madigan Army Medical Center
2021-10-14 – 2025-12 · Nasal Polyps, Sinusitis, Chronic Disease
What this study did
Early phase / not applicable (6)
Atopic Dermatitis
NCT04878770 · Erasmus Medical Center
2021-08-16 – 2025-01-01 · Dermatitis, Atopic
What this study did
NCT06509243 · Medical University of Silesia
2023-02-10 – 2024-04-10 · Atopic Dermatitis
What this study did
NCT03983460 · Association pour la Recherche Clinique et Immunologique
2020-03-09 – 2021-09 · Atopic Dermatitis
What this study did
NCT04066998 · Centre Hospitalier Universitaire de Besancon
2019-12 – 2021-08 · Conjunctival Diseases, Atopic Dermatitis, Side Effect
What this study did
Other / comorbidity
NCT06501807 · University Hospital, Lille
2024-07-11 – 2035-01-02 · Rhinosinusitis Chronic, Nasal Polyps
What this study did
NCT06743581 · Centre hospitalier de l'Université de Montréal (CHUM)
2025-08-19 – 2030-02 · Non-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant Therapy
What this study did
Used as active comparator (22)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (8)
Atopic Dermatitis
NCT07783425 · Pfizer
2026-08-24 – 2029-06-15 · Atopic Dermatitis
What this study did
NCT07754786 · Innovent Biologics (Suzhou) Co. Ltd.
2026-09-15 – 2028-08-26 · Atopic Dermatitis
What this study did
NCT06884891 · Qilu Pharmaceutical Co., Ltd.
2025-04 – 2028-04 · Atopic Dermatitis
What this study did
NCT07386743 · Jiangsu Genscend Biopharmaceutical Co., Ltd
2026-01-29 – 2028-01 · Atopic Dermatitis (AD)
What this study did
NCT04345367 · Pfizer
2020-06-11 – 2021-07-13 · Atopic Dermatitis
What this study did
NCT03720470 · Pfizer
2018-10-29 – 2020-03-06 · Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
What this study did
Chronic Spontaneous Urticaria
NCT06868212 · Novartis Pharmaceuticals
2025-07-11 – 2027-05-17 · Chronic Spontaneous Urticaria (CSU)
What this study did
Phase 2 (5)
Atopic Dermatitis
NCT07399067 · Innovent Biologics (Suzhou) Co. Ltd.
2026-02-06 – 2027-05-27 · Atopic Dermatitis
What this study did
NCT07330934 · Innovent Biologics (Suzhou) Co. Ltd.
2025-12-31 – 2026-08-18 · Atopic Dermatitis
What this study did
NCT06881251 · Janssen Research & Development, LLC
2025-02-26 – 2026-04-07 · Dermatitis, Atopic
What this study did
NCT05470114 · LEO Pharma
2022-05-19 – 2023-10-09 · Atopic Dermatitis
What this study did
NCT04791319 · Janssen Research & Development, LLC
2021-05-03 – 2022-03-31 · Dermatitis, Atopic
What this study did
Phase 1 (8)
Atopic Dermatitis
NCT07027527 · Apogee Therapeutics, Inc.
2025-06-04 – 2027-12 · Atopic Dermatitis
What this study did
NCT07358156 · Chong Kun Dang Pharmaceutical
2026-02-09 – 2026-11-16 · Atopic Dermatitis
What this study did
NCT07411755 · Jiangsu Genscend Biopharmaceutical Co., Ltd
2026-03-05 – 2026-08-24 · Atopic Dermatitis (AD)
What this study did
NCT06193434 · Innovent Biologics (Suzhou) Co. Ltd.
2024-01-05 – 2025-08-20 · Healthy Participants, Atopic Dermatitis Patients
What this study did
NCT06614907 · Qilu Pharmaceutical Co., Ltd.
2024-08-31 – 2024-12-27 · Atopic Dermatitis
What this study did
Other / comorbidity
NCT07791342 · Mabwell (Shanghai) Bioscience Co., Ltd.
2026-04-22 – 2026-08-17 · Healthy Participants
What this study did
NCT07334496 · Gan & Lee Pharmaceuticals.
2026-03-09 – 2026-07-17 · Biosimilarity
What this study did
NCT07502534 · Innovent Biologics (Suzhou) Co. Ltd.
2026-04-24 – 2026-07-07 · Healthy Volunteers
What this study did
Phase 4 (1)
Other / comorbidity
NCT07268313 · Copenhagen University Hospital, Rigshospitalet
2025-04-03 – 2027-06-01 · Nasal Polyps
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 4 (1)
Atopic Dermatitis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1 (1)
Other / comorbidity
NCT06369467 · Regeneron Pharmaceuticals
2024-05-17 – 2027-08-31 · Food Allergy
What this study did
Phase 4 (1)
Atopic Dermatitis
NCT06465732 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-01 – 2026-07 · Atopic Dermatitis
What this study did

Competitive landscape

This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Chronic Obstructive Pulmonary Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dupilumab (Dupixent): this drugApprovedMonoclonal antibodyIL-4R-alphaPartial signal
NCT04456673: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.295 Exacerbation per participant-year (95% CI 1.048 to 1.6) | Dupilumab 300 mg q2w 0.859 Exacerbation per participant-year (95% CI 0.699 to 1.057)
NCT03930732: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.01 exacerbation per participant-year (95% CI 0.931 to 1.301) | Dupilumab 300 mg q2w 0.776 exacerbation per participant-year (95% CI 0.645 to 0.934)
Aclidinium Bromide (Tudorza Pressair)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT03022097: Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L.
NCT00891462: Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1) (Change from Baseline to 12 weeks): Aclidinium Bromide, 200µg 0.062 L (Standard Error 0.015) | Aclidinium Bromide, 400µg 0.099 L (Standard Error 0.015) vs Placebo -0.025 L (Standard Error 0.015)
Aclidinium Bromide / Formoterol Fumarate (Duaklir Pressair)
ApprovedUS marketing discontinued
Small moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptorPartial signal
NCT03022097: Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013)
NCT02796677: Week 24, AB/FF 400/12 ug: 1-hour post-dose FEV1 vs aclidinium 400 ug +0.084 L (95% CI 0.051 to 0.117), p<0.0001; trough FEV1 vs formoterol 12 ug +0.055 L (95% CI 0.023 to 0.088), p=0.0009. Monotherapy primary: aclidinium vs tiotropium trough FEV1 +0.007 L (95% CI -0.021 to 0.035), non-inferior at the -50 mL margin (CT.gov posted results).
Budesonide / Formoterol Fumarate (SYMBICORT)ApprovedCombinationGlucocorticoid receptor; Beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere)ApprovedSmall moleculeGlucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicReliable signal
NCT02465567: Rate of moderate/severe COPD exacerbations: PT010 (the trial's investigational triple therapy) reduced the rate by 24% vs glycopyrronium/formoterol fumarate (PT003) (p<0.001), and by 13% vs budesonide/formoterol fumarate (PT009) (p=0.003)
NCT02497001: Primary 1, FEV1 AUC0-4 at week 24, BGF MDI vs BFF MDI: LS mean difference 116 mL (95% CI 80 to 152; p<0.0001), met. Primary 2, change from baseline in morning pre-dose trough FEV1 at week 24, BGF MDI vs GFF MDI: 13 mL (95% CI -9 to 36; p=0.2375), missed. Separate Europe/Canada analysis over 24 weeks: FEV1 AUC0-4 vs BFF MDI +104 mL (95% CI 77 to 131; p<0.0001) and vs BUD/FORM DPI +91 mL (p<0.0001); trough FEV1 vs GFF MDI +22 mL (95% CI 4 to 39; p=0.0139), all met.
Ensifentrine (Ohtuvayre)ApprovedSmall moleculePDE3/PDE4Reliable signal
NCT05743075: Placebo-corrected change from baseline in FEV1 AUC0-12h at Week 12: +110 mL for ensifentrine (p<0.0001)
NCT04535986: Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12 (Baseline (pre-dose on Day 1) and Week 12): Ensifentrine 0.0611 liters (Standard Error 0.01825) vs Placebo -0.0256 liters (Standard Error 0.0195)
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signal
NCT02164513: Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001)
NCT02345161: Co-primary 1, trough FEV1 change to week 24 (ITT): +142 mL with FF/UMEC/VI vs -29 mL with budesonide/formoterol (LS mean difference 171 mL, 95% CI 148 to 194; P<0.001), met. Co-primary 2, SGRQ total score change to week 24 (ITT): -6.6 vs -4.3 units (LS mean difference -2.2, 95% CI -3.5 to -1.0; P<0.001), met. Supportive week-52 analyses in the extension subset: FEV1 difference 179 mL (95% CI 131 to 226; P<0.001); SGRQ difference -2.7 (95% CI -5.5 to 0.2; P=0.065), not significant.
Fluticasone Furoate / Vilanterol (Breo Ellipta)ApprovedSmall moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT01313676: Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Placebo — Dead: 275 Participants; Alive: 3832 Participants; Unknown: 4 Participants | Fluticasone Furoate 100 µg — Dead: 251 Participants; Alive: 3884 Participants; Unknown: 0 Participants | Vilanterol 25 µg — Dead: 265 Participants; Alive: 3853 Participants; Unknown: 0 Participants | Fluticasone Furoate/Vilanterol 100/25 µg — Dead: 246 Participants; Alive: 3874 Participants; Unknown: 1 Participants missed
Fluticasone Propionate / Salmeterol (Advair Diskus)ApprovedSmall moleculeGlucocorticoid receptor / Beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Glycopyrrolate / Formoterol Fumarate (Bevespi Aerosphere)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptorWeak signalFeatured results are non-efficacy only in this race
IpratropiumApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)not yet gradedNo reviewed efficacy summary in this indication
Ipratropium / AlbuterolApprovedSmall moleculeMuscarinic M3 receptor / Beta-2 adrenergic receptor (combination)not yet gradedNo reviewed efficacy summary in this indication
Mepolizumab (Nucala)ApprovedMonoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingPartial signal
NCT04133909: Annualized Rate of Moderate or Severe Exacerbations (Up to Week 104): Mepolizumab 100 mg 0.8 Exacerbations per year (95% CI 0.7 to 0.91) | Placebo 1.01 Exacerbations per year (95% CI 0.89 to 1.15)
OlodaterolApprovedSmall moleculeBeta-2 adrenergic receptorReliable signal
NCT00782210: FEV1 AUC0-3h response at Day 85 (Week 12), difference from placebo: olodaterol 5 mcg +0.172 L (SE 0.019), P<0.0001; olodaterol 10 mcg +0.176 L (SE 0.019), P<0.0001 (study 1222.11, n=624).
NCT00796653: Week 24, olodaterol 5 and 10 ug vs placebo: FEV1 AUC0-3h +0.129 and +0.154 L (both p<0.0001); trough FEV1 +0.053 L (p=0.0055) and +0.069 L (p=0.0003); TDI focal score in this study +0.402 (p=0.1999) and +0.419 (p=0.1818), not significant; TDI in the combined analysis +0.509 (p=0.0270) and +0.525 (p=0.0203) (CT.gov posted results).
Olodaterol / Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Revefenacin (Yupelri)ApprovedSmall moleculeMuscarinic receptors (antagonist)Reliable signal
NCT05046795: Trough FEV1 on Day 85 (Baseline and Day 85): Revefenacin Inhalation Solution 175 mcg QD. 55.12 mL (Standard Error 23.974) vs Placebo Inhalation Solution QD. -95.78 mL (Standard Error 24.504)
NCT02459080: Study 0126: trough FEV1 change at day 85 vs placebo +79 mL with revefenacin 88 µg (p=0.0003) and +146 mL with revefenacin 175 µg (p<0.0001).
Roflumilast (Daliresp)ApprovedSmall moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
Salmeterol (DISKUS)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT02172287: Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant.
Umeclidinium (Incruse Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Reliable signal
NCT02184611: Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001)
NCT01387230: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 (Baseline and Day 85): Placebo -0.007 Liters (Standard Error 0.028) | UMEC 62.5 µg 0.12 Liters (Standard Error 0.0257) | UMEC 125 µg 0.145 Liters (Standard Error 0.0268)
Umeclidinium / VilanterolApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptorReliable signal
NCT01777334: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115)
NCT01716520: Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour Forced Expiratory Volume in One Second (FEV1) Obtained Post-dose at Day 14 of Each Treatment Period (TP) by Response Type (Baseline and Day 14 of each treatment period (up to study day 83)): UMEC/VI 62.5/25 µg — Responder to UMEC, n=90, 90, 88: 0.337 Liters (Standard Error 0.0166); Responder to VI, n=99, 102, 100: 0.331 Liters (Standard Error 0.0148); Responder to Neither, n=36, 37, 36: 0.13 Liters (Standard Error 0.0243) vs UMEC 62.5 µg — Responder to UMEC, n=90, 90, 88: 0.216 Liters (Standard Error 0.0166); Responder to VI, n=99, 102, 100: 0.189 Liters (Standard Error 0.015); Responder to Neither, n=36, 37, 36: 0.077 Liters (Standard Error 0.0243) | VI 25 µg — Responder to UMEC, n=90, 90, 88: 0.201 Liters (Standard Error 0.0167); Responder to VI, n=99, 102, 100: 0.233 Liters (Standard Error 0.0147); Responder to Neither, n=36, 37, 36: 0.057 Liters (Standard Error 0.024)
AstegolimabPhase 3Monoclonal antibodyST2 (IL1RL1)Partial signal
NCT05595642: ARNASA (NCT05595642), primary endpoint annualized COPD exacerbation rate (AER) at 52 weeks: astegolimab showed a numerical 14.5% reduction vs placebo, not statistically significant missed
NCT05037929: Annualized COPD exacerbation rate reduced by a statistically significant 15.4% vs placebo at 52 weeks with every-two-weeks dosing
Beclomethasone Dipropionate / Formoterol FumaratePhase 3Small moleculeGlucocorticoid receptor; β2-adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow)Phase 3Small moleculeGlucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signalNo reviewed efficacy summary in this indication
DepemokimabPhase 3Monoclonal antibodyIL-5not yet gradedNo reviewed efficacy summary in this indication
FelcorekibartPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
HSK39004Phase 3Small moleculePhosphodiesterase 3 and Phosphodiesterase 4 (PDE3/PDE4)not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 3Antibody-derived scaffoldTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
REGEND001Phase 3Cell therapyAirway epithelial regeneration (autologous basal cells)Partial signalNo reviewed efficacy summary in this indication
Tezepelumab (Tezspire)Phase 3Monoclonal antibodyTSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizingnot yet gradedNo reviewed efficacy summary in this indication
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
TozorakimabPhase 3Monoclonal antibodyIL-33Partial signal
NCT06040086: Primary endpoint met: statistically significant reduction in the annualised rate of moderate-to-severe COPD exacerbations in former smokers and the overall population (MIRANDA, AstraZeneca, 2026-04-20).
NCT05158387: Primary endpoint met: tozorakimab reduced the annualised rate of moderate-to-severe COPD exacerbations vs placebo in former smokers and the overall population (TITANIA, 2026-03-27).
TQC3721Phase 3Small moleculePDE3/PDE4Partial signal
NCT06527144: Primary endpoint, change in peak FEV1 at week 4 vs placebo: 3 mg +100 mL (95% CI 41 to 159; P = .0011); 6 mg +147 mL (95% CI 93 to 201; P < .0001) (PACER-II, CHEST 2026).
StapokibartPhase 2/3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
9MW1911Phase 2Monoclonal antibodyIL-33/ST2, ST2 (IL1RL1)Weak signalFeatured results are safety only in this race
AlvelestatPhase 2Small moleculeNeutrophil elastasePartial signal
NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively).
AZD6793Phase 2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
DexpramipexolePhase 2Small moleculeEosinophil maturation/survival (mitochondrial)not yet gradedNo reviewed efficacy summary in this indication
GlasmacinalPhase 2Small moleculeAirway epithelial barrier integrityPartial signal
NCT05516316: Primary endpoint (BALF IL-8 after inhaled LPS challenge, 375 mg EP395 daily for 3 weeks vs placebo) not met. BALF IL-6, TNF-alpha, MIP-1alpha, MIP-1beta and MCP-1 were lower and IL-33, IL-8, IL-1beta, neutrophil elastase and myeloperoxidase higher with EP395 (none statistically significant). Serum SP-D rose with EP395 (mean 148.8 to 183.0 ng/mL at 24 h, p=0.0007) but not with placebo. missed
HRS-9821Phase 2Small moleculePDE3/PDE4Weak signalNo reviewed efficacy summary in this indication
OcankitugPhase 2Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
PBF-680Phase 2—Adenosine A1 receptornot yet gradedNo reviewed efficacy summary in this indication
PegtarazimodPhase 2PeptideComplement C1q / neutrophil effectors (myeloperoxidase, NETosis)not yet gradedNo reviewed efficacy summary in this indication
RademikibartPhase 2Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
RC1416Phase 2Multispecific antibodyIL-4 / IL-5 / IL-13not yet gradedNo reviewed efficacy summary in this indication
RSS0343Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
SolizmestrocelPhase 2Cell therapyRegenerative/anti-inflammatory (MSC)Weak signalNo reviewed efficacy summary in this indication
VerekitugPhase 2Monoclonal antibodyTSLP receptornot yet gradedNo reviewed efficacy summary in this indication
WIN378Phase 2Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
XKH001Phase 2Monoclonal antibodyIL-25not yet gradedNo reviewed efficacy summary in this indication
KIT2014Phase 1/2PeptidePDE3/PDE4not yet gradedNo reviewed efficacy summary in this indication
APG808
Phase 1(overall)
Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
BBT002Phase 1Multispecific antibodyIL-4Ralpha / IL-5not yet gradedNo reviewed efficacy summary in this indication
FrevecitinibPhase 1Small moleculeJAK1/2/3/TYK2Weak signalNo reviewed efficacy summary in this indication
GDC-6988Phase 1Small moleculeTMEM16A (Anoctamin-1) calcium-activated chloride channelnot yet gradedNo reviewed efficacy summary in this indication
GSK3862995Phase 1Monoclonal antibodyIL-33not yet gradedNo reviewed efficacy summary in this indication
PUR1800Phase 1Small moleculeNarrow-spectrum kinase (p38/Syk-family)not yet gradedNo reviewed efficacy summary in this indication
REGEND007Phase 1Cell therapyAirway basal layer stem cellsnot yet gradedNo reviewed efficacy summary in this indication
Ensifentrine / Glycopyrrolate
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
GSK6759821
—(overall)
RNA / oligonucleotide—not yet gradedNo reviewed efficacy summary in this indication
RG6527
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
ItepekimabDiscontinuedMonoclonal antibodyIL-33Partial signal
NCT04701983: Annualized rate of moderate/severe AECOPD, reduction vs placebo at Week 52: 27% (every-2-week dosing arm), statistically significant primary endpoint met
NCT04751487: AERIFY-2 (NCT04751487), annualized rate of moderate/severe AECOPD exacerbations vs placebo at Week 52 (the primary-endpoint timepoint): 2% reduction with itepekimab every-2-weeks, 12% reduction with itepekimab every-4-weeks; neither reached statistical significance missed

Large race: only the 63 furthest-along competitors are listed; 1 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(35 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Dupixent (dupilumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (1)
Phase 3Atopic DermatitisActive not recruiting
Est. primary completion 2026-11 · NCT06389136 · CT.gov ↗
What to watch
December 2026 (3)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-01 · NCT06088771 · CT.gov ↗
What to watch
Phase 2Hypereosinophilic SyndromeRecruiting
Est. primary completion 2026-12-30 · NCT06477653 · CT.gov ↗
What to watch
Phase 2AsthmaActive not recruiting
Est. primary completion 2026-12-31 · NCT05347771 · CT.gov ↗
What to watch
2027 (18)
January 2027 (2)
Phase 4AsthmaActive not recruiting
Est. primary completion 2027-01 · NCT03694158 · CT.gov ↗
What to watch
Phase 2/3Skin Inflammation, Allergic Contact DermatitisActive not recruiting
Est. primary completion 2027-01-01 · NCT05535738 · CT.gov ↗
What to watch
February 2027 (1)
Phase 4Atopic DermatitisNot yet recruiting
Est. primary completion 2027-02-07 · NCT07905547 · CT.gov ↗
What to watch
March 2027 (2)
Phase 1Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast CancerRecruiting
Est. primary completion 2027-03-10 · NCT06637306 · CT.gov ↗
What to watch
Phase 4AsthmaActive not recruiting
Est. primary completion 2027-03-16 · NCT05097287 · CT.gov ↗
What to watch
April 2027 (2)
Phase 4AsthmaActive not recruiting
Est. primary completion 2027-04-24 · NCT06572228 · CT.gov ↗
What to watch
Phase 4Atopic DermatitisActive not recruiting
Est. primary completion 2027-04-29 · NCT05983068 · CT.gov ↗
What to watch
June 2027 (3)
Phase 4Atopic DermatitisRecruiting
Est. primary completion 2027-06 · NCT05042258 · CT.gov ↗
What to watch
Phase 3PruritusRecruiting
Est. primary completion 2027-06-02 · NCT05263206 · CT.gov ↗
What to watch
Phase 4AsthmaRecruiting
Est. primary completion 2027-06-30 · NCT06385236 · CT.gov ↗
What to watch
July 2027 (1)
Phase 4Atopic DermatitisRecruiting
Est. primary completion 2027-07 · NCT05268107 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Prurigo NodularisRecruiting
Est. primary completion 2027-10-28 · NCT06293053 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Alopecia AreataRecruiting
Est. primary completion 2027-11-30 · NCT05551793 · CT.gov ↗
What to watch
December 2027 (5)
Phase 1Eosinophilic EsophagitisEnrolling by invitation
Est. primary completion 2027-12 · NCT07358234 · CT.gov ↗
What to watch
Phase 4AsthmaRecruiting
Est. primary completion 2027-12 · NCT04743791 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant TherapyRecruiting
Est. primary completion 2027-12 · NCT06743581 · CT.gov ↗
What to watch
Phase 2PruritisRecruiting
Est. primary completion 2027-12-31 · NCT06226610 · CT.gov ↗
What to watch
Phase 4AsthmaRecruiting
Est. primary completion 2027-12-31 · NCT06818019 · CT.gov ↗
What to watch
2028 (9)
February 2028 (2)
Phase 4Atopic DermatitisRecruiting
Est. primary completion 2028-02-01 · NCT05858619 · CT.gov ↗
What to watch
Phase 2Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-DependentRecruiting
Est. primary completion 2028-02-28 · NCT07091175 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Atopic DermatitisNot yet recruiting
Est. primary completion 2028-05-02 · NCT07919899 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Eosinophilic EsophagitisRecruiting
Est. primary completion 2028-06-19 · NCT07112378 · CT.gov ↗
What to watch
July 2028 (1)
Phase 4Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2028-07-30 · NCT07587658 · CT.gov ↗
What to watch
December 2028 (4)
Phase 2Major Depressive DisorderRecruiting
Est. primary completion 2028-12 · NCT07908563 · CT.gov ↗
What to watch
Phase 3AsthmaEnrolling by invitation
Est. primary completion 2028-12-21 · NCT06191315 · CT.gov ↗
What to watch
Phase 4Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2028-12-23 · NCT07053423 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal Cancer, Liver MetastasesRecruiting
Est. primary completion 2028-12-31 · NCT07277322 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 3AsthmaRecruiting
Est. primary completion 2029-01 · NCT07309614 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Alopecia AreataRecruiting
Est. primary completion 2029-03-31 · NCT05866562 · CT.gov ↗
What to watch
2031 (1)
June 2031 (1)
Phase 1Skin DiseasesRecruiting
Est. primary completion 2031-06-30 · NCT05649098 · CT.gov ↗
What to watch
2034 (1)
September 2034 (1)
Early phase / not applicableRhinosinusitis Chronic, Nasal PolypsRecruiting
Est. primary completion 2034-09-02 · NCT06501807 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(9)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 April 2026ApprovalFDA approves Dupixent for CSU in children aged 2 to 11
US, FDA · Source ↗
13 April 2026ApprovalDupixent approved in the EU for CSU in children aged 2 to 11
EU, EMA · Source ↗
April 2026FDA action dateFDA decision expected by April 2026 for CSU in children
US, FDA · Source ↗
24 March 2026ApprovalDupixent approved in Japan for bullous pemphigoid
JP, MHLW · Source ↗
27 February 2026Filing acceptedFDA accepts sBLA for Dupixent in children 2-11 with CSU
US, FDA · Source ↗
24 February 2026ApprovalFDA approves Dupixent for allergic fungal rhinosinusitis
US, FDA · Source ↗
18 April 2025ApprovalDupixent approved in the US for chronic spontaneous urticaria
US, FDA · Source ↗
18 February 2025Filing acceptedDupixent sBLA accepted by FDA for bullous pemphigoid
US, FDA · Source ↗
18 February 2025Priority reviewFDA priority review for Dupixent in bullous pemphigoid
US, FDA · Source ↗